Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced/ Metastatic Her-2 Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05654532
What this trial is testing

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 100
Early research (Phase 1)Study completedNCT03944499
What this trial is testing

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.

Who this might be right for
Solid TumorBreast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 161
Testing effectiveness (Phase 2)Ended earlyNCT00130507
What this trial is testing

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 14
Large-scale testing (Phase 3)Looking for participantsNCT07377643
What this trial is testing

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 540
Early research (Phase 1)Study completedNCT03767335
What this trial is testing

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Menarini Group 62
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05501886
What this trial is testing

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

Who this might be right for
Breast Cancer
Celcuity Inc 701
Early research (Phase 1)Ended earlyNCT00634088
What this trial is testing

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
R-Pharm 13
Large-scale testing (Phase 3)Looking for participantsNCT06954961
What this trial is testing

Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 640
Large-scale testing (Phase 3)Study completedNCT02514681
What this trial is testing

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Locally Advanced or Metastatic Breast Cancer
Japan Breast Cancer Research Group 226
Large-scale testing (Phase 3)Study completedNCT00876395
What this trial is testing

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 719
Early research (Phase 1)Ended earlyNCT03429101
What this trial is testing

Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Spectrum Pharmaceuticals, Inc 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Testing effectiveness (Phase 2)Study completedNCT04420598
What this trial is testing

DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease

Who this might be right for
Advanced Breast CancerHER2-positive Breast CancerBrain Metastases+1 more
MedSIR 41
Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Ended earlyNCT01185509
What this trial is testing

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 31
Early research (Phase 1)Looking for participantsNCT07029399
What this trial is testing

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
HR+ Breast CancerTriple Negative Breast Cancer (TNBC)CCNE1 Amplified Advanced Solid Tumors+1 more
NiKang Therapeutics, Inc. 361
Testing effectiveness (Phase 2)Looking for participantsNCT07610720
What this trial is testing

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2-Positive Metastatic Breast Cancer
Sun Yat-sen University 57
Next Page